Serpentovirus / Nidovirus (Python Respiratory Infection)

Serpentovirus, also known as nidovirus, is an enveloped, positive-sense single-stranded RNA virus belonging to the family Tobaniviridae, subfamily Serpentovirinae. It is a significant cause of respiratory disease in pythons, particularly in captive collections. The virus primarily targets the respiratory epithelium, leading to proliferative and inflammatory lesions in the upper and lower respiratory tracts. Clinically, it manifests as stomatitis, rhinitis, tracheitis, and pneumonia, often with secondary bacterial infections. The disease is highly contagious and can cause substantial morbidity and mortality in affected collections. Accurate diagnosis requires molecular testing (RT-PCR) and histopathology, as clinical signs may mimic other respiratory pathogens. Management focuses on supportive care, antimicrobial therapy for secondary infections, and strict biosecurity to prevent spread.

The causative agent is serpentovirus, a nidovirus in the subfamily Serpentovirinae. Multiple species have been identified, including Python nidovirus 1 (PnV-1) and other related strains. These viruses are enveloped, pleomorphic, and approximately 120-160 nm in diameter. The genome is a single-stranded positive-sense RNA molecule of about 30-33 kb, encoding non-structural proteins (replicase) and structural proteins (spike, membrane, nucleocapsid). The virus exhibits tropism for respiratory epithelial cells, causing cytopathic effects and proliferation. Transmission occurs horizontally via direct contact with respiratory secretions, fomites, and possibly aerosolization. The virus can persist in the environment, especially in moist conditions. Stress, poor husbandry, and immunosuppression predispose to clinical disease. Co-infections with other pathogens (e.g., bacteria, fungi, other viruses) are common and exacerbate severity.

Serpentovirus infections have been reported in various python species, including ball pythons (Python regius), Burmese pythons (Python bivittatus), reticulated pythons (Malayopython reticulatus), and others. It is also found in other snake families, such as colubrids and vipers, but pythons are particularly susceptible. The disease is more prevalent in captive collections, especially those with high stocking density, poor ventilation, and inadequate quarantine protocols. Wild populations may also be affected, but data are limited. Age and sex predilections are not well-defined, but juveniles and immunocompromised individuals may be more severely affected. Outbreaks can cause high morbidity (up to 100%) and variable mortality (10-80%). The virus is endemic in some breeding facilities, leading to chronic carrier states. Seasonal patterns may correlate with temperature and humidity fluctuations. Introduction of new snakes without quarantine is a major risk factor for outbreaks.

The virus enters the host via the respiratory route, infecting epithelial cells of the nasal passages, trachea, and lungs. Replication occurs in the cytoplasm, leading to cell lysis and necrosis. The host immune response, including inflammatory cell infiltration (heterophils, macrophages, lymphocytes), contributes to tissue damage. Proliferative lesions, such as epithelial hyperplasia and squamous metaplasia, may develop in the respiratory tract. In severe cases, the virus can spread to other organs, including the gastrointestinal tract, liver, and kidneys, via viremia. Secondary bacterial infections (e.g., Pseudomonas, Aeromonas, Mycoplasma) are common due to mucosal damage and immunosuppression. The resulting pneumonia can lead to hypoxia, respiratory acidosis, and death. Chronic infections may result in fibrosis and permanent respiratory impairment. The virus may also cause immunosuppression, increasing susceptibility to other pathogens.

Intrinsic factors include species susceptibility (pythons, especially ball pythons), age (young snakes may be more susceptible), and immune status. Extrinsic factors include suboptimal husbandry: inadequate temperature gradients (below 80°F for pythons), low humidity (below 50%), poor ventilation, and overcrowding. Stress from handling, transport, or recent introduction to a new environment increases susceptibility. Poor sanitation, such as infrequent cleaning of enclosures and shared equipment, facilitates viral transmission. Inadequate quarantine of new arrivals (less than 90 days) is a major risk. Nutritional deficiencies, particularly vitamin A and C, may impair mucosal immunity. Concurrent infections (e.g., inclusion body disease, paramyxovirus) can exacerbate disease. Environmental factors like high ammonia levels from waste accumulation can damage respiratory epithelium.

Clinical signs vary from subclinical to severe. Early signs include mild nasal discharge, occasional open-mouth breathing, and increased respiratory effort. As disease progresses, snakes may exhibit mucoid or purulent nasal discharge, stomatitis with oral plaques, and audible wheezing or crackles. Severe cases show dyspnea, tachypnea, and cyanosis. Affected snakes often become anorexic, lethargic, and may assume abnormal postures (e.g., head elevated to facilitate breathing). Weight loss and dehydration are common. In some cases, neurological signs (e.g., incoordination, head tilt) may occur if the virus spreads to the central nervous system. Secondary bacterial pneumonia can lead to systemic signs such as septicemia. Chronic carriers may show intermittent mild signs, especially during stress. Physical examination may reveal oral erythema, excessive mucus, and abnormal lung sounds on auscultation (though challenging in snakes).

1. Inclusion Body Disease (IBD): Caused by reptarenavirus; presents with neurological signs (stargazing, disorientation) and regurgitation, but respiratory signs are less prominent. Diagnosis via PCR on blood or tissues; histopathology shows intracytoplasmic inclusion bodies. 2. Paramyxovirus (Fer-de-Lance virus): Causes respiratory and neurological signs; PCR and serology available; histopathology shows syncytial cells. 3. Bacterial pneumonia (e.g., Pseudomonas, Aeromonas, Mycoplasma): Often secondary; culture and sensitivity from tracheal wash or lung aspirate; responds to antibiotics. 4. Fungal pneumonia (e.g., Aspergillus): Chronic weight loss, dyspnea; radiography may show pulmonary masses; cytology and culture. 5. Parasitic pneumonia (e.g., Rhabdias, Entamoeba): Fecal examination and tracheal wash; treat with antiparasitics. 6. Foreign body or trauma: History and imaging. 7. Neoplasia (e.g., pulmonary adenocarcinoma): Radiography and biopsy. 8. Nutritional deficiency (e.g., vitamin A): Oral and respiratory epithelial changes; respond to supplementation.

1. Clinical triage: Isolate affected snakes immediately. Obtain thorough history (source, quarantine, husbandry, recent additions). 2. Physical examination: Observe respiratory effort, nasal discharge, oral cavity, and body condition. Use minimal restraint to avoid stress. 3. Sample collection: For RT-PCR, use swabs of the choanal slit, tracheal wash, or lung aspirate. Blood for PCR and serology (if available). 4. Imaging: Obtain dorsoventral and lateral radiographs to assess lung fields for consolidation or masses. 5. Endoscopy: If feasible, perform tracheoscopy or bronchoscopy to visualize lesions and collect biopsies. 6. Laboratory: Complete blood count and plasma biochemistry to assess inflammation and organ function. 7. Confirmatory testing: RT-PCR for serpentovirus on respiratory samples or tissues. Histopathology on biopsy or necropsy samples. 8. Rule out differentials: Bacterial culture and sensitivity, fungal culture, PCR for other viruses (IBD, paramyxovirus). 9. Postmortem: If death occurs, perform necropsy with histopathology and PCR on lung, trachea, and other tissues.

Hematology: In snakes, heterophils are the primary granulocytes. Leukocytosis with heterophilia may be seen in bacterial infections, but viral infections may cause lymphocytosis or lymphopenia. PCV may be decreased due to chronic disease. Thrombocytopenia may occur. Biochemistry: Non-specific changes include elevated AST and CK due to muscle damage from struggling or secondary myositis. Uric acid may be elevated with dehydration or renal involvement. Electrolyte imbalances (e.g., hyperkalemia) may occur with severe tissue damage. Fecal analysis: May reveal secondary parasites. PCR: RT-PCR on respiratory swabs or tissues is the gold standard for diagnosis. Serology: Virus neutralization or ELISA may be available but not widely used. Urinalysis: Not commonly performed in snakes, but may show urates. Cytology: Tracheal wash or lung aspirate may show inflammatory cells and possibly viral inclusion bodies.

Radiography: In snakes, the lungs are elongated and extend from the heart to the caudal coelom. In pythons, the right lung is functional, while the left is vestigial. Radiographs may show increased opacity in the lung fields, consolidation, or air bronchograms. Pleural effusion is rare. Ultrasonography: Can be used to assess lung parenchyma and detect fluid or masses, but is limited by air. CT: Provides detailed images of the respiratory tract and can detect early lesions, but is expensive and requires anesthesia. MRI: Useful for evaluating soft tissue and neurological involvement. Endoscopy: Rigid endoscopy can be used to visualize the trachea and primary bronchi, collect swabs, and biopsy lesions. It is particularly useful for diagnosing proliferative tracheitis.

Cytology: Tracheal wash or lung aspirate may show heterophilic inflammation, macrophages, and necrotic debris. Intracytoplasmic inclusion bodies may be seen in some cases. Histopathology: Characteristic lesions include proliferative tracheitis and bronchitis with epithelial hyperplasia, squamous metaplasia, and infiltration of heterophils and lymphocytes. The lungs may show interstitial pneumonia, edema, and necrosis. In chronic cases, fibrosis and goblet cell hyperplasia are seen. Intracytoplasmic inclusion bodies may be present in epithelial cells. Immunohistochemistry can confirm viral antigen. Electron microscopy may reveal viral particles.

Treatment is primarily supportive, as no specific antiviral therapy is available. 1. Isolation: Immediately isolate affected snakes to prevent spread. 2. Supportive care: Maintain optimal temperature (85-90°F for pythons) and humidity (60-70%). Provide fluid therapy: subcutaneous or intraosseous fluids (e.g., 20-30 ml/kg/day of isotonic crystalloids). 3. Nutritional support: If anorexic, assist-feed with a blenderized diet via stomach tube. 4. Antimicrobial therapy: For secondary bacterial infections, use broad-spectrum antibiotics based on culture and sensitivity. Common choices include ceftazidime (20 mg/kg IM q72h) or enrofloxacin (5-10 mg/kg IM q24h). 5. Nebulization: Use nebulized antibiotics (e.g., amikacin 5 mg/kg diluted in saline) or mucolytics (e.g., N-acetylcysteine) for 15-20 minutes twice daily. 6. Anti-inflammatory: NSAIDs like meloxicam (0.2 mg/kg PO q24h) may reduce inflammation. 7. Antiviral: No proven antiviral for serpentovirus; some clinicians use famciclovir (30 mg/kg PO q24h) but efficacy is unproven. 8. Surgical: In cases of abscesses or granulomas, surgical debridement may be considered. 9. Husbandry corrections: Improve ventilation, reduce stocking density, and ensure proper sanitation.

Prognosis is guarded to poor, especially in severe cases with secondary infections. Mild cases may recover with supportive care, but many snakes become chronic carriers. Mortality can be high in outbreaks. Negative prognostic indicators include severe dyspnea, cyanosis, anorexia, and weight loss. Early diagnosis and aggressive supportive care improve outcomes. Chronic carriers may have intermittent clinical signs and can shed virus, posing a risk to other snakes. Long-term prognosis for breeding animals is poor due to the risk of transmission. Euthanasia may be considered for severely affected individuals to prevent suffering and spread.

Recheck affected snakes every 1-2 weeks during treatment. Monitor weight, respiratory effort, and appetite. Repeat PCR on respiratory swabs at 4-6 weeks after clinical resolution to assess viral clearance. For chronic carriers, perform PCR every 3-6 months. Maintain strict quarantine for at least 90 days after resolution. For collections, implement biosecurity protocols: separate tools, disinfect enclosures with appropriate virucides (e.g., accelerated hydrogen peroxide), and test new arrivals. Provide annual health checks including PCR for serpentovirus in high-risk collections. Educate owners on proper husbandry to reduce stress.

Pearls: 1. Use a sterile swab to sample the choanal slit for PCR; this is less invasive than tracheal wash. 2. Nebulization with antibiotics can be effective for respiratory infections. 3. Maintain optimal humidity to prevent drying of respiratory mucosa. 4. Use a pediatric stethoscope to auscultate the lungs in snakes. 5. Always perform a thorough oral examination to detect stomatitis. Pitfalls: 1. Do not use corticosteroids in reptiles as they are immunosuppressive. 2. Avoid using aminoglycosides in dehydrated snakes due to nephrotoxicity. 3. Do not rely solely on clinical signs; confirm with PCR. 4. Do not neglect secondary bacterial infections; they are common. 5. Avoid overcrowding and poor ventilation, which exacerbate disease. 6. Do not use fipronil in reptiles as it is toxic.

Based on Carpenter's Exotic Animal Formulary (6th ed.): 1. Ceftazidime: 20 mg/kg IM q72h for bacterial pneumonia. 2. Enrofloxacin: 5-10 mg/kg IM or PO q24h; may cause tissue irritation. 3. Amikacin: 5 mg/kg IM q72h, then q48h; monitor renal function. 4. Meloxicam: 0.2 mg/kg PO q24h for anti-inflammatory. 5. Fluids: Isotonic crystalloids (e.g., Normosol-R) at 20-30 ml/kg/day SC or IO. 6. Nebulization: Amikacin (5 mg/kg diluted in 10 ml saline) or ceftazidime (20 mg/kg) for 15-20 min q12h. 7. N-acetylcysteine: 10-20 mg/kg nebulized q12h as mucolytic. 8. Famciclovir: 30 mg/kg PO q24h (unproven). 9. Vitamin A: 1000-2000 IU/kg IM once weekly for 2-4 weeks if deficient. 10. Probiotics: Not well-studied but may be used.

Serpentovirus was first identified in 2014 in pythons with respiratory disease (Stenglein et al., 2014). Subsequent studies have characterized the virus and its pathogenesis. A study by Dervas et al. (2019) described the pathology in ball pythons, noting proliferative tracheitis and pneumonia. Experimental infection studies have confirmed Koch's postulates (Dervas et al., 2020). Treatment remains supportive, with no specific antiviral. A consensus statement from the Association of Reptilian and Amphibian Veterinarians (ARAV) recommends PCR testing and strict biosecurity. Research on vaccines is ongoing but not yet available. The virus is considered a significant threat to python collections, and screening is recommended for breeding facilities.